A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients (Q34278778)

1 August 2017

1 reference

title

A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients (English)

1 reference

1 August 2017

Khalil ME

1

1 reference

1 August 2017

Basher AW

series ordinal

2

1 reference

1 August 2017

Brown EJ Jr

series ordinal

3

1 reference

1 August 2017

Alhaddad IA

series ordinal

4

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

Journal of the American College of Cardiology

1 August 2017

1 reference

1 August 2017

37

1 reference

1 August 2017

7

1 reference

1 August 2017

1757-1764

1 reference

Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Hemodynamic effects of captopril in patients with severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Comparative hemodynamic and clinical effects of long-term treatment with prazosin and captopril for severe chronic congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

A cooperative multicenter study of captopril in congestive heart failure: hemodynamic effects and long-term response.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Enalapril in congestive heart failure: acute and chronic invasive hemodynamic evaluation.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Clinical and hemodynamic experience with enalapril in congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Acute hemodynamic and hormonal effects of ramipril in chronic congestive heart failure and comparison with captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Modulation of hemodynamic effects with a converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observations on long-term clinical, functional, and biochemical res

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Hemodynamic effects of lisinopril after long-term administration in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Renin, aldosterone and cardiac decompensation: Studies with an oral converting enzyme inhibitor in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

A placebo-controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Fosinopril Heart Failure Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Effects of once-daily benazepril therapy on exercise tolerance and manifestations of chronic congestive heart failure. The Benazepril Heart Failure Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. The Quinapril Heart Failure Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Absence of effect on exercise capacity of 12-weeks treatment with ramipril in patients with moderate congestive heart failure. Ramipril Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Effects of enalapril on long-term mortality in severe congestive heart failure. CONSENSUS Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

The Effect of the Angiotensin-Converting–Enzyme Inhibitor Zofenopril on Mortality and Morbidity after Anterior Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Comparison of enalapril versus captopril on left ventricular function and survival three months after acute myocardial infarction (the "PRACTICAL" study)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Influence of chronic captopril therapy on the infarcted left ventricle of the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Targeting pathological remodeling: concepts of cardioprotection and reparation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Angiotensin-converting enzyme inhibition and the progression of congestive cardiomyopathy. Effects on left ventricular and myocyte structure and function

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Divergent effects of angiotensin-converting enzyme inhibition and angiotensin II-receptor antagonism on myocardial cellular proliferation and collagen deposition after myocardial infarction in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Discrepancy between plasma and lung angiotensin-converting enzyme activity in experimental congestive heart failure. A novel aspect of endothelium dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Cofactors of constitutive nitric oxide synthase and endothelium-dependent relaxations in canine femoral veins

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Prevention of endothelial dysfunction in small and large arteries in a model of chronic heart failure. Effect of angiotensin converting enzyme inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Emerging concepts: angiotensin-converting enzyme inhibition in coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Captopril reduced plasminogen activator inhibitor activity in patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Chronic oral pretreatment with the angiotensin converting enzyme inhibitor, trandolapril decreases ventricular fibrillation in acute ischaemia and reperfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Cardiac arrhythmias are ameliorated by local inhibition of angiotensin formation and bradykinin degradation with the converting-enzyme inhibitor ramipril

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Enalapril decreases plasma noradrenaline levels during the cold pressor test in human hypertensives

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Endothelium-Derived Bradykinin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Postischemic antiarrhythmic effects of angiotensin-converting enzyme inhibitors. Role of suppression of endogenous endothelin secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphism in coronary disease and malignant ventricular arrhythmias.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Effects of early captopril administration on infarct expansion, left ventricular remodeling and exercise capacity after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Early angiotensin converting enzyme inhibitor therapy after experimental myocardial infarction prevents left ventricular dilation by reducing infarct expansion: a possible mechanism of clinical benefits

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Expansion of transmural myocardial infarction: a pathophysiologic factor in cardiac rupture

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Effects of early enalapril treatment on global and regional wall motion in acute myocardial infarction. CONSENSUS II Multi Echo Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Effect of enalapril initiated early after acute myocardial infarction on heart failure parameters, with reference to clinical class and echocardiographic determinants. CONSENSUS II Multi-Echo Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Benefit of converting enzyme inhibition on left ventricular volumes and ejection fraction in patients receiving beta-blockade after myocardial infarction. CONSENSUS II multiecho study group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Effect of long-term captopril therapy on left ventricular remodeling and function during healing of canine myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Acute effects of delayed reperfusion on myocardial infarct shape and left ventricular volume: a potential mechanism of additional benefits from thrombolytic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Angiotensin-converting enzyme inhibitor use in survivors of acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Management of refractory congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Early use of ACE inhibitors in the treatment of acute myocardial infarction in the United States: experience from the National Registry of Myocardial Infarction 2. National Registry of Myocardial Infarction 2 participants

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

A Comparison of the Cough Profile of Fosinopril and Enalapril in Hypertensive Patients with a History of ACE Inhibitor-Associated Cough

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901229-3

7 January 2021

10.1016/S0735-1097(01)01229-3

Identifiers

DOI

1 reference

1 August 2017

1 reference